Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine.
作者： Donna M. Graham , Natasha B. Leighl
关键词:
摘要: A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted many new therapies becoming available for patients with advanced disease. Stratification treatment by histologic and molecular subtype is recommended order to obtain greatest clinical benefit while minimizing adverse effects treatment. However, these advances diagnosis NSCLC have come at a financial cost. This review highlights economic impact screening abnormalities targeted NSCLC. Major determinants cost are drug acquisition testing. As technologies advance, testing costs may reduce. we must collaborate payers manufacturers ensure that high do not limit patient accessibility potentially beneficial
frontiersin.org
core.ac.uk 
sci-hub.se 参考文章(52)
Gilberto de Lima Lopes, Joel E. Segel, Daniel S. W. Tan, Young K. Do, Tony Mok, Eric A. Finkelstein, Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung Cancer. ,vol. 118, pp. 1032- 1039 ,(2012) , 10.1002/CNCR.26372
Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra K. Grevstad, Carol M. Moinpour, Scott D. Ramsey, Antoinette J. Wozniak, Geoffrey R. Weiss, Dennis F. Moore, Valerie K. Israel, Robert B. Livingston, David R. Gandara, Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Journal of Clinical Oncology. ,vol. 19, pp. 3210- 3218 ,(2001) , 10.1200/JCO.2001.19.13.3210
B F El-Rayes, P M LoRusso, Targeting the epidermal growth factor receptor. British Journal of Cancer. ,vol. 91, pp. 418- 424 ,(2004) , 10.1038/SJ.BJC.6601921
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Journal of Thoracic Oncology. ,vol. 8, pp. 823- 859 ,(2013) , 10.1097/JTO.0B013E318290868F
Eunhee S. Yi, Jennifer M. Boland, Joseph J. Maleszewski, Anja C. Roden, Andre M. Oliveira, Marie-Christine Aubry, Michele R. Erickson-Johnson, Bolette L. Caron, Yan Li, Hui Tang, Shawn Stoddard, Jason Wampfler, Kimary Kulig, Ping Yang, Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH Journal of Thoracic Oncology. ,vol. 6, pp. 459- 465 ,(2011) , 10.1097/JTO.0B013E318209EDB9
Mari Mino-Kenudson, Lucian R Chirieac, Kenny Law, Jason L Hornick, Neal Lindeman, Eugene J Mark, David W Cohen, Bruce E Johnson, Pasi A Jänne, A John Iafrate, Scott J Rodig, None, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clinical Cancer Research. ,vol. 16, pp. 1561- 1571 ,(2010) , 10.1158/1078-0432.CCR-09-2845
Nicole Mittmann, William K. Evans, Angela Rocchi, Christopher J. Longo, Heather-Jane Au, Don Husereau, Natasha B. Leighl, Pierre K. Isogai, Murray D. Krahn, Stuart Peacock, Deborah Marshall, Doug Coyle, Suzanne C. Malfair Taylor, Philip Jacobs, Paul I. Oh, Guidelines for health technologies: specific guidance for oncology products in Canada. Value in Health. ,vol. 15, pp. 580- 585 ,(2012) , 10.1016/J.JVAL.2011.12.006
Jin Ho Paik, Gheeyoung Choe, Hyojin Kim, Ji-Young Choe, Hyun Ju Lee, Choon-Taek Lee, Jong Seok Lee, Sanghoon Jheon, Jin-Haeng Chung, Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization Journal of Thoracic Oncology. ,vol. 6, pp. 466- 472 ,(2011) , 10.1097/JTO.0B013E31820B82E8
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl, A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 6, pp. 1379- 1391 ,(2011) , 10.1097/JTO.0B013E318220CB8E
S. Kamel-Reid, G. Chong, D.N. Ionescu, A.M. Magliocco, A. Spatz, M. Tsao, X. Weng, S. Young, T. Zhang, D. Soulieres, EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer Current Oncology. ,vol. 19, pp. 67- 74 ,(2012) , 10.3747/CO.19.862